Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective

Abstract

Dapagliflozin is likely to be cost-effective when used as an adjunct therapy to standard care compared with standard care alone for the treatment of chronic heart failure and reduced ejection fraction.